What is a clinical trial?
Clinical trials provide the latest in medical treatments for cancer before they are made available to the general public as standard treatment. Treatments are administered under carefully controlled conditions, which allow doctors and researchers to learn about their effectiveness, as well as possible side effects. Patients are carefully selected, to be sure the treatment is appropriate for their particular disease and current state of health. Participants will work with doctors and health care professionals at every stage of a clinical trial.
Some patients choose to participate in clinical trials in hopes of a better response to treatment or increase in survival by using newer drugs or therapies. Some patients feel that participation in clinical trials will help others - family, friends, or even strangers - as well as themselves. Many patients feel the close follow-up and re-testing schedules used to check results of the treatment on a clinical trial ensures a thorough schedule of care.
To see if you are eligible for a clinical trial…
Look through our list of open trials below to find your type of cancer. Then, if any of them seem to fit and you would like more information, contact the Sutter Pacific Medical Foundation Clinical Trials Office at (707) 523-7316.
- A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy (HER2 status determined by study lab)
- Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone to Chemo Plus Trastuzuab in Women with Node Positive or High-Risk Node Negative HER2 Low Invasive Breast Cancer.
- Randomized Phase II Study to Estimate the Effect of Prophylactic Intervention with Naproxene or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
- Randomized, single-blind study to estimate the effect of patient education on reported bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim.
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated With Surgery.
- A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
- A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumabfor Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
- A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin, Paclitaxel, & Bevacizumab with/without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung CA
- A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/ Paclitaxel/Erlotinib or Erlotinib Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS 2) Selected by Serum Proteomics
- Double-Blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered Once Every 3 Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multicycle Chemotherapy
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
- A Ph. III Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF v600 Mutation-Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma
- Phase II Trial of the Aurora Kinase Inhibitor MLN8237 in Relapsed/Refractory Peripheral T-Cell Non-Hodgkin’s Lymphoma
- A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- Phase II Study of Oxaliplatin, Capecitabine, and Radiation in pre-operative Therapy of Rectal Cancer
- EVErolimus for Renal Cancer. A Phase III Study. (Intermediate, High Risk or Very High Risk)
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell CA